Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Eight-Week, Double-Blind, Group-Sequential Design, Placebo Controlled Trial To Evaluate The Safety And Efficacy Of The Co- Administration Of Sertraline And Elzasonan (CP-448,187) In Outpatients With Major Depressive Disorder

NCT00275197 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00275197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00275197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Eight-Week, Double-Blind, Group-Sequential Design, Placebo Controlled Trial To Evaluate The Safety And Efficacy Of The Co- Administration Of Sertraline And Elzasonan (CP-448,187) In Outpatients With Major Depressive Disorder
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2005
Completion date
July 31, 2007
Enrollment
262 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major